For US Health-care Professionals Only
sanofi pasteur: The vaccines division of sanofi-aventis Group
Menactra Age Indications - Protection for a broader range of patients

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.1

Menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by N meningitidis serogroup B. Menactra vaccine is not to be used to treat meningococcal infections or for immunization against diphtheria.1

Physicians are reminded that no vaccine protects 100% of recipients from disease.